Literature DB >> 24853905

Cardiovascular biomarkers in preeclampsia at triage.

Sven Wellmann1, Jörg Benzing, Silvia Fleischlin, Nils Morgenthaler, Sotirios Fouzas, Christoph A Bührer, Gabor Szinnai, Tilo Burkhardt, Olav Lapaire.   

Abstract

INTRODUCTION: To investigate the ability of cardiovascular plasma biomarkers to identify imminent preeclampsia (PE) among pregnant women at triage.
MATERIAL AND METHODS: C-terminal pro-arginine vasopressin (copeptin), C-terminal pro-endothelin-1 (CT-proET-1), mid-regional pro-adrenomedullin (MR-proADM), and mid-regional pro-atrial natriuretic peptide (MR-proANP) were prospectively measured in pregnant women presenting at the obstetrical triage units of the University Hospitals of Basel and Zurich, Switzerland. Logistic regression and receiver operating characteristics (ROC) analysis was used to assess and quantify the predictive ability of cardiovascular biomarkers.
RESULTS: Of the 147 included women, 27 (18.4%) were diagnosed at admission with PE. All biomarker levels were significantly higher in participants with PE as compared to controls. However, only MR-proANP, MR-proADM and CT-proET-1 were significant and independent predictors of PE, after taking into account the effect of various clinical confounders. The area under the ROC curve (AUC) was 0.62 (95% confidence interval 0.50-0.73) for copeptin, 0.64 (0.52-0.76) for MR-proADM, 0.71 (0.61-0.82) for CT-proET-1, and 0.83 (0.73-0.92) for MR-proANP. The combination of MR-proANP and MR-proADM resulted in the highest diagnostic performance (AUC 0.88; 0.79-0.96). DISCUSSION: Assessment of the cardiovascular plasma biomarkers MR-proANP and MR-proADM holds promise to support diagnosis of PE at triage.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24853905     DOI: 10.1159/000361016

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  7 in total

1.  Midregional pro-adrenomedullin plasma concentrations are blunted in severe preeclampsia.

Authors:  B C Matson; R W Corty; N O Karpinich; A P Murtha; W Valdar; C A Grotegut; K M Caron
Journal:  Placenta       Date:  2014-07-10       Impact factor: 3.481

2.  Selective Serotonin Reuptake Inhibitor Use in Pregnancy and Protective Mechanisms in Preeclampsia.

Authors:  Julie A Vignato; S Banu Gumusoglu; Heather A Davis; Sabrina M Scroggins; Wendy S Hamilton; Debra S Brandt; Gary L Pierce; Boyd A Knosp; Donna A Santillan; Mark K Santillan
Journal:  Reprod Sci       Date:  2022-08-19       Impact factor: 2.924

3.  Increased levels of copeptin before clinical diagnosis of preeclampsia.

Authors:  Edwina H Yeung; Aiyi Liu; James L Mills; Cuilin Zhang; Tuija Männistö; Zhaohui Lu; Michael Y Tsai; Pauline Mendola
Journal:  Hypertension       Date:  2014-09-15       Impact factor: 10.190

4.  Copeptin: a new biomarker that is specific for preeclampsia?

Authors:  Denise C Cornelius
Journal:  Hypertension       Date:  2014-09-15       Impact factor: 10.190

5.  Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort - a prospective cohort study.

Authors:  Katrina Suzanne Evers; Evelyn Annegret Huhn; Sotirios Fouzas; Christian Barro; Jens Kuhle; Urs Fisch; Luca Bernasconi; Olav Lapaire; Sven Wellmann
Journal:  BMC Pregnancy Childbirth       Date:  2019-11-05       Impact factor: 3.007

6.  Copeptin in Patients with Pregnancy-Induced Hypertension.

Authors:  Agnieszka Marek; Rafał Stojko; Agnieszka Drosdzol-Cop
Journal:  Int J Environ Res Public Health       Date:  2021-06-15       Impact factor: 3.390

7.  Serum copeptin and pregnancy outcome in preeclampsia.

Authors:  Kehinde Sola Akinlade; Isaac Oluwole Adediji; Sheu Kadiri Rahamon; Adeniran Olubukola Fawole; Olukemi Oluwatoyin Tongo
Journal:  Niger Med J       Date:  2015 Sep-Oct
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.